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Neurodegenerative and psychiatric diseases (NPDs) are today’s most important group 
of diseases, surpassing both atherosclerotic cardiovascular disease and cancer in 
morbidity incidence. Although NPDs have a dramatic impact on our society because of 
their high incidence, mortality, and severe debilitating character, remarkably few effective 
interventions have become available. The current treatments, if available, comprise the 
lifelong intake of general immunosuppressants to delay disease progression or neu-
rotransmitter antagonists/agonists to dampen undesired behaviors. The long-term usage 
of such medication, however, coincides with often severe adverse side effects. There is, 
therefore, an urgent need for safe and effective treatments for these diseases. Here, 
we discuss that many NPDs coincide with subtle chronic or flaring brain inflammation 
sometimes escalating with infiltrations of lymphocytes in the inflamed brain parts causing 
mild to severe or even lethal brain damage. Thus, NPDs show all features of autoimmune 
diseases. In this review, we postulate that NPDs resemble autoimmune-driven inflam-
matory diseases in many aspects and may belong to the same disease spectrum. Just 
like in autoimmune diseases, NPD symptoms basically are manifestations of a chronic 
self-sustaining inflammatory process with detrimental consequences for the patient. 
Specific inhibition of the destructive immune responses in the brain, leaving the patient’s 
immune system intact, would be the ultimate solution to cure patients from the disease. 
To reach this goal, the primary targets, e.g., the primary self-antigens (pSAgs) of the 
patient’s chronic (auto)immune response, need to be identified. For a few major NPDs, 
immunological studies led to the identification of the pSAgs involved in the autoimmune 
damage of specific brain parts. However, further research is needed to complete the list 
of pSAgs for all NPDs. Such immunological studies will not only provide crucial insights 
into NPD pathogenesis but also ultimately enable the development of a new generation 
of safe and effective immunotherapies for NPDs. Interventions that will dramatically 
improve the life expectancy and quality of life of individual patients and, moreover, will 
significantly reduce the health-care costs of the society in general.
Keywords: neurodegenerative disease, psychiatric disease, chronic inflammation, immune tolerance, 
self-antigen, viral vector, reverse vaccine
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THe CAUSe OF DeGeNeRATive 
DiSeASeS
The immune system comprises an intricate network of tissues, 
cells, and molecules responsible for responding to pathogen 
infection, malignant cells, and wounding, and thus for maintain-
ing the body’s homeostasis.
The first line of active immunity, named innate immunity, 
is activated by general evolutionary conserved pathogen- 
associated molecular patterns (PAMPs) released from infected 
cells or damage-associated molecular patterns (DAMPs) 
released by malignant and wounded cells (1). Cells of the innate 
immune system carry a variety of cytoplasmic and membrane-
bound pattern recognition receptors to sense and respond to 
PAMPs and DAMPs. Upon binding of these alarm signals, the 
innate immune cells remove the cognate pathogens, damaged, 
or malignant cells and, when necessary, activate the second line 
of immunity, named adaptive immunity. Our adaptive immune 
system consists of humoral and cellular components. Humoral 
adaptive immunity is mediated by B lymphocytes (B  cells), 
which secrete antibodies, whereas cellular adaptive immunity 
is mediated by T lymphocytes (T cells), which secrete cytokines 
and are capable of destroying damaged, malignant, or infected 
cells. The adaptive immune system acts via the activation of 
antigen-specific cell clones, which means that each clone of B or 
T cells bears a different receptor that binds antigenic peptides 
(epitopes) with a high specificity. Where B  cells directly bind 
antigen epitopes, recognition by T  cells requires presentation 
of antigen epitopes on major histocompatibility complex 
molecules.
During homeostasis, the adaptive immune system is in the 
tolerance mode. Immune tolerance is actively maintained by 
homeostatic interactions between somatic cells and innate 
immune cells with lymphocytes wherein the lymphocytes have 
a regulatory role by suppressing immune responses to self and 
foreign antigens (2, 3).
When PAMPs or DAMPs released by infected, wounded, and 
malignant cells are perceived by innate immune cells, inflam-
masomes assemble in the cytoplasm and a local inflammatory 
response is initiated. Inflammation is a highly orchestrated cas-
cade of protective local and systemic events aimed at confining 
the pathogen, reducing the cell damage, promoting wound repair, 
and removing malignant cells (4). When all necroptotic cellular 
components, PAMPs, and DAMPs are removed, the inflamma-
tion stops and the homeostasis is restored. Usually, in healthy 
individuals, the repair activity of the innate immune system is 
sufficient to maintain homeostasis.
However, in the case the infection is too widespread, the 
wound is too big or the malignancy grows too fast, and the innate 
immune cells are not able to remove all the necroptotic cellular 
components, PAMPs, and DAMPs in time, cells of the adaptive 
immune system will infiltrate the inflamed area, locally break the 
immune tolerance in an antigen-specific manner, and destroy the 
infected, injured, or malignant cells (5). The destroyed and thus 
necroptotic cells further enhance the cellular immune response 
and speed-up the wound repair process (6). Again, after such 
a normal wound repair response, when all necroptotic cellular 
components, PAMPs, or DAMPs are removed, inflammation 
stops and the tolerance toward self will be restored (7).
In the case an adaptive immune response to self for whatever 
reason remains active, the wound repair process becomes self-
sustaining and chronic. Chronic or flaring immune responses to 
tissue-specific antigens coincide with amyloid plaque formation, 
hypervascularization, fibrosis, and tissue scarification (jointly 
named sclerosis) at the site of inflammation. Wound healing is 
a beneficial process, but chronic self-sustaining wound healing 
is detrimental to the affected tissue and will result in the devel-
opment of a degenerative disease (8–11). In this process, the 
self-antigen-specific chronic or repeated stimulation of a cellular 
immune response is the cause and driver of pathogenesis and thus 
disease progression (12).
The incidence of degenerative diseases associated with chronic 
or flaring immune responses, such as obesity, diabetes mellitus, 
arthritis, atherosclerotic cardiovascular disease, and NPDs, is 
increasing rapidly in our aging population. The reason for this 
increase has remained unclear. With a global population of 
more than seven billion individuals, we are a highly successful 
mammalian species. Several hypotheses have been formulated to 
explain our success. One of them says that we have developed 
an extremely efficient immune system that enables us to reach 
a high age under extremely challenging biotic and abiotic envi-
ronmental conditions. The down-side of having such an efficient 
or “tensed” immune system is the increased risk of developing 
undesired immune responses to self-components, resulting in 
autoimmune diseases, or to harmless non-self-components, 
resulting in allergies.
THe CAUSe OF THe CAUSe OF 
DeGeNeRATive DiSeASeS
The majority of degenerative diseases are sporadic (idiopathic 
or acquired) diseases, and because the immune responses in 
patients are directed to tissue-specific self-antigens, these dis-
eases are classified as autoimmune diseases. Examples of well-
studied autoimmune diseases include diabetes mellitus type 1 
(DM1), rheumatoid arthritis (RA), and multiple sclerosis (MS). 
For these diseases, the causal relationships between chronic 
immune activation, pathogenesis, and disease symptom devel-
opment have been demonstrated in experimentally induced 
animal models. Autoimmune diseases are the result of an 
interplay between environmental stimuli, such as diet, lifestyle, 
trauma, exposure to microbes, pathogens, or toxic compounds 
(smoking), and the possession of predisposing gene alleles, 
which ultimately at a certain moment in time “trigger” a sus-
tained loss of self-tolerance resulting in an immune-mediated 
damage of autologous tissues (13). Frequently, patients with an 
autoimmune disease have an increased susceptibility to develop 
other autoimmune diseases. Genes involved in innate or adap-
tive immunity, such as antigen uptake, processing, presentation, 
and signaling, represent the strongest predisposing genetic 
factors (14). This indicates that exposure to environmental 
trigger stimuli is the cause of aberrant immune responses to 
self-antigens, which on its turn is the cause of the development 
of the characteristic disease symptoms.
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In patients with a pathogen-induced degenerative disease, 
such as viral hepatitis and the acquired immune deficiency syn-
drome, the causal trigger stimuli are chronic infections resulting 
in a continuous release of PAMPs by the infected and necroptotic 
cells. This results in chronic self-sustaining immune reactions 
directed against antigens derived from the pathogen. In case the 
pathogen-derived antigens mimic self-antigens (molecular mim-
icry), a chronic immune response will be induced in the tissue 
that expresses the mimicked self-antigens. There are indications 
that retroviral elements and chronic infections with herpesviruses 
such as Epstein–Barr virus or cytomegalovirus are associated with 
a number of autoimmune diseases, including NPDs with relaps-
ing and remitting phases. Harmless bacteria may elicit an errone-
ous chronic immune response. In principle, such a response to 
harmless microbe-derived antigens is an allergic response. When 
the microbe-derived antigens mimic self-antigens, autoimmune 
diseases may be induced in predisposed individuals. Examples of 
bacteria-derived NPDs are the Guillain–Barré syndrome caused 
by Campylobacter jejuni and Lyme disease caused by tick-borne 
Borrelia burgdorferi infections.
The majority of degenerative diseases, however, result from an 
improper restoration of immune tolerance to specific self-antigens 
after a normal wound repair response. The incapacity to restore 
immune tolerance in a particular organ or tissue may occur when 
DAMPs are over-abundantly released inducing a hyperimmune 
response, when DAMPs continuously keep emerging, or when 
lymphocytes and tissue cells interact aberrantly during a wound 
repair response.
In humans with a degenerative disease, it is almost impossible 
to identify the primary targets of the activated T cells (the primary 
self-antigens, pSAgs), since the sustained destructive immune 
responses manifest often years after the onset, basically as the 
characteristic disease symptoms resulting from the tissue dam-
age. Most efforts to identify the pSAgs of a degenerative disease 
have been dedicated to verifying humoral immune responses in 
patients with the disease. These studies have revealed the pres-
ence of autoantibodies in the sera of patients that usually bind to 
intracellular components which are released in the blood after tis-
sue degeneration. Because the studies are performed with blood 
samples from patients who have the disease for a relatively long 
time, many of the identified antibody targets represent secondary 
self-antigens, which may also be post-translationally modified by 
the pathogenic process.
Acute autoimmune encephalitis is a rare group of NPDs diag-
nosed by the presence of autoantibodies in the sera of patients 
that bind hippocampal self-antigens (15). In approximately half 
of the cases, the encephalitis is caused by the presence of tumors 
in patients that express and present neo-antigens that are identi-
cal to the hippocampal self-antigens. In the other half of the cases, 
it is assumed that infections with unknown viruses or microbes 
are the cause of the encephalitis (16, 17).
For a long time, the role of cellular immunity in the tissue 
destruction has been underestimated. Only recently, it has 
become clear that T cells play a predominant role in the tissue 
destruction in patients with a degenerative disease. For a number 
of degenerative diseases, studies on the variability of T cells that 
infiltrate the inflamed tissue of a patient, like, for example, the 
anterior horns of the spinal cords of amyotrophic lateral scle-
rosis (ALS) patients and the hippocampus of epilepsy patients, 
revealed that the infiltrating T cells comprise a single or few cell 
clones, indicating that a cellular adaptive immune response to 
one or few self-antigens is responsible for the autoimmune tissue 
damage (18, 19). Therefore, immunological studies focusing on 
cellular immune responses to self-antigens, preferably in early 
onset patients, may be the preferred method to identify the pSAgs 
of the disease.
A more feasible approach to demonstrate the causal relation-
ship between chronic immunity to a pSAg and disease symptom 
development is to immunize animals with a pSAg of a degenerative 
disease. Immunization of animals with a secondary self-antigen 
does not lead to the induction of disease symptoms, because there 
is a massive immune tolerance present and actively maintained 
to these proteins in the non-inflamed body parts. The now clas-
sical immunization experiments with pSAgs have not only led 
to the identification of the pSAgs of degenerative diseases but 
also to the development of the currently used and most valuable 
inducible animal models of human degenerative diseases, such 
as the myelin oligodendrocyte glycoprotein (MOG)/myelin basic 
protein (MBP)-induced rodent and marmoset experimental 
autoimmune encephalitis (EAE) models resembling human 
MS, the proinsulin-induced mouse model of human DM1 and 
the collagen type 2-induced rodent and marmoset collagen type 
2-induced arthritis models resembling human RA. The pSAgs 
of degenerative diseases identified thus far are tissue-specific 
extracellular matrix proteins, cytoskeleton-associated proteins, 
or components involved in intercellular signaling. Secondary 
self-antigens are generally cytoplasmic proteins present in 
different tissues and are targeted relatively late by the patients’ 
immune system when the affected tissue is chronically inflamed 
in a process referred to as epitope spreading.
In analogy to the Koch’s postulates for identifying the causal 
relation between pathogens and infectious diseases, pSAgs of 
degenerative diseases have to fulfill the following three criteria:
 1. the pSAg of a degenerative disease is predominantly or exclu-
sively expressed in the affected tissue.
 2. induction of an adaptive immune response to the pSAg in an 
animal results in the development of the disease.
 3. all patients have an adaptive immune response to the pSAg, 
while these are absent in healthy people.
With the exception of MS, the role of the immune system in 
NPD pathogenesis is relatively poorly studied. Only for a few NPDs 
solid immunological studies in animals and patients have been 
employed to identify the pSAgs of the disease. Immunological 
follow-up studies for other NPDs are highly desired, because 
they will not only provide key insights into the pathogenesis 
of this group of diseases but also result in new targets for drug 
development.
THe CANDiDATe pSAgs OF NPDs
Neurodegenerative and psychiatric diseases are associated with 
chronic or flaring inflammation of specific brain areas with infil-
tration of peripheral immune cells, resulting in mild or severe 
TAble 1 | Candidate primary self-antigens (pSAgs) of neurodegenerative and psychiatric diseases.
Group Neuron type Disease Affected brain part pSAg
1 Cholinergic Multiple sclerosis White matter Myelin oligodendrocyte 
glycoprotein, myelin basic protein
Alzheimer’s dementia Basal forebrain Neurofilament heavy
Amyotrophic lateral sclerosis Motor neurons Neurofilament light
Autism spectrum disorder (autism, Asperger syndrome, 
PDD-NOS)
Striatum, cerebellum Muscarine acetyl choline receptors
2 Dopaminergic Huntington disease Striatum Huntingtin
Parkinson disease Substantia nigra compactum and VTegm Vesicular monoamine transporter-2
Attention-deficit hyperactivity disorder Mesostriatal system Dopamine transporter-1
Reward deficiency syndrome (addiction, obsessive–
compulsive disorder)
Striatum Dopamine receptor-1, 2, 3
3 Glutamatergic Epilepsy (temporal lobe epilepsy) Hippocampus metabotropic Glutamate receptor 3
Schizophrenia Hippocampus N-methyl-D-aspartate receptor
4 Histaminergic Tic diseases (Tourette syndrome) Basal ganglia Histamine 3 receptor
5 Serotonergic Depression Prefrontal cortex 5-hydroxytryptamine transporter
Anxiety Brain stem 5-hydroxytryptamine receptor 2C
The identification of the candidate pSAgs is based on the combination of different lines of research as indicated in Section “The Candidate Primary Self-Antigens of NPDs.”
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brain damage that leads to the development of the characteristic 
disease symptoms. Based on the type of neurotransmitter used for 
signaling by the affected neurons the diseases can be categorized 
in groups (See Table 1).
In patients with a familial neurodegenerative disease, such as 
Huntington disease (HD), and the familial forms of Alzheimer’s 
dementia (AD), Parkinson disease (PD), ALS, and epilepsy with 
accumulated genetically predestinated cellular defects, DAMPs 
originating from necroptotic cells continuously emerge in a 
specific brain part. As a consequence of this, a self-sustaining 
immune response to tissue-specific self-antigens is induced in the 
brains of patients. However, a major part of the neurodegenera-
tive diseases (and all psychiatric diseases) is sporadic, meaning 
that the trigger environmental stimulus is unknown.
Neurodegenerative diseases are the result of the presence of 
predisposing gene alleles (risk genes) interacting with unknown 
environmental stimuli, such as trauma, infection, or exposure, to 
toxic compounds. The immune reactions in neurodegenerative 
diseases (HD, PD, MS, AD, ALS, and epilepsy) usually are severe 
and associated with massive amyloid deposition (huntingtin, 
alpha-synuclein, Abeta, tau, TDP-43, etc.) and sclerosis at the 
affected brain part, often resulting in a fatal loss of function.
Psychiatric diseases are the result of the presence of risk genes 
determining the personality interacting with environmental 
stimuli, such as psychosocial factors, lifestyle, and stress. In 
contrast to neurodegenerative diseases, the CNS inflammation 
and immunity in the psychiatric diseases is mild, with barely 
detectable damage to the affected brain part [attention-deficit 
hyperactivity disorder (ADHD), addiction, reward deficiency 
syndrome (RDS), depression, anxiety, autism spectrum disorder 
(ASD), schizophrenia, and Tic disease (TD)] (20).
Neurodegenerative and psychiatric diseases can be progres-
sive (HD, PD, ADHD, RDS, AD, ALS, and ASD) or relapsing-
remitting (anxiety, depression, MS, epilepsy, schizophrenia, and 
TD). For these diseases, the immune responses flare. During 
relapses, the immune tolerance is broken and the symptoms are 
worse and during remissions, the immune tolerance is intact and 
the disease does not progress.
For the majority of NPDs, the pSAgs involved in the brain 
damage await identification and there is only indirect evidence 
what they could be (See Table  1, last column). For this latter 
group of diseases imaging, pharmacological and genetic studies 
using knockout and knockdown mouse mutants revealed a num-
ber of candidate pSAgs, but immunological studies as outlined 
in the previous paragraph are needed to confirm their role in the 
disease pathology.
Group 1: Cholinergic NPDs
Multiple Sclerosis
Multiple sclerosis is characterized by chronic inflammation and 
degeneration of cholinergic myelinated axons in the brain and 
spinal cord, resulting in functional disability and premature 
death (21). Analysis of the T  cell receptors (TCRs) present on 
the surface of cytotoxic T lymphocytes (CTLs) that infiltrate the 
inflamed brain parts revealed that these CTLs have a strongly 
biased TCR repertoire compared to splenic CTLs. This suggests 
that the infiltrating CTLs recognize a single or few self-antigens 
(8, 22). Immunization of animals with MOG or MBP or peptides 
derived thereof results in the development of EAE that shares 
similarities with human MS (23). Since MOG and MBP fulfill the 
three criteria outlined in Section “The cause of the cause of degen-
erative diseases,” these two proteins are candidate pSAgs involved 
in the autoimmune inflammatory/demyelination of cholinergic 
neurons in the CNS white matter MS patients.
Alzheimer’s Dementia
Alzheimer’s dementia is the most common cause of aging-
related dementia, associated with chronic inflammation and 
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T lymphocyte-mediated degeneration of cholinergic myelinated 
large axons in the basal forebrain, resulting in severe cognitive 
impairment and eventually death (24–26). Rats immunized with 
adjuvated extracts of cholinergic neurons from the electric fish, 
Torpedo, develop experimental autoimmune dementia (EAD) 
resembling human AD (27). It was found that the intermediate 
neurofilament heavy (NFH) protein is the most likely pSAg in 
these extracts, capable of inducing EAD in rats (28). Almost 
all diagnosed AD patients have a humoral immune response 
to NFH, but not to the intermediate neurofilament light (NFL) 
protein (29, 30). Since NFH fulfills the three criteria outlined in 
Section “The cause of the cause of degenerative diseases,” this 
neurofilament is a candidate pSAg involved in the autoimmune 
cortex destruction in AD patients.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is characterized by progressive 
muscle weakness (paresis), disability, and eventually death, with 
a median survival of 3–5 years. The motor cortex and the anterior 
horn of the spinal cord of ALS patients are chronically inflamed 
and infiltrated with macrophages and CTLs, resulting in the loss 
of cholinergic myelinated motor axons (31–35). Immunization of 
guinea pigs with adjuvated bovine motor neuron extracts induces 
experimental autoimmune motor neuron disease (EAMD) 
resembling human ALS (36). Immunization of mice with NFL 
results in the development of spastic paresis resembling EAMD 
(37). It has further been reported that almost all diagnosed ALS 
patients have antibodies against NFL (38–40). Since NFL fulfills 
the three criteria outlined in Section “The cause of the cause of 
degenerative diseases,” it is believed that neurofilament is a can-
didate pSAg involved in the autoimmune destruction of motor 
neurons in ALS patients.
Autism Spectrum Disorders
Autism spectrum disorder, including autism, the Asperger 
syndrome and the pervasive developmental disorder-not 
otherwise specified (PDD-NOS) represent a group of NPDs 
involving cholinergic neurons in the dorsomedial striatum 
and cerebellum characterized by often severe repetitive 
behaviors and cognitive inflexibility manifested as an impaired 
development of social interaction and communication skills 
and a markedly restricted repertoire of activity and inter-
est. ASD coincides with chronic inflammation and altered 
immune responses in the affected brain parts (41–43). Studies 
in rats demonstrated that antagonists of muscarine acetyl 
choline receptors (mAChRs) increase and mAChR agonists 
reduce the repetitive behaviors (44, 45). Treatment of mouse 
models of human ASD with acetylcholine esterase inhibitors 
resulting in increased synaptic acetylcholine levels leads to 
an improvement of the behavioral rigidity (46). Destruction 
of cholinergic neurons in the dorsomedial striatum leads to 
increased repetitive behaviors that can be alleviated by treat-
ment with M1 mAChR agonists (47), suggesting that the loss 
of cholinergic signaling by the autoimmune damage to the M1 
mAChR-bearing neurons in the dorsomedial striatum results 
in the development of ASD.
Group 2: Dopaminergic NPDs
Huntington Disease
Huntington disease is a progressive and usually fatal neurode-
generative disease of the striatum associated with the gradual loss 
of dopaminergic striatal neurons involved in motor coordination 
and subcortical dementia. The disease is caused by mutations in 
the gene encoding huntingtin, resulting in the chronic deposi-
tion of huntingtin amyloid in the striatum that coincides with 
a chronic immune response to a striatum-specific self-antigen 
(possibly huntingtin) and a gradual loss of dopaminergic striatal 
neurons (48).
Parkinson Disease
Parkinson disease is the most common neurodegenerative dis-
ease at younger age. PD symptoms include tremor, uncontrolled 
movements (bradykinesia), muscle stiffness, impaired posture 
and balance, loss of automatic movements, addiction, and loss 
of cognitive functions. PD coincides with chronic inflamma-
tion and T  lymphocyte infiltration of the dopamine-producing 
neurons in the substantia nigra compactum and ventral 
tegmentum (49) and a gradual loss of dopamine-producing 
neurons (50–52). Immunization of mice or guinea pigs with 
dopaminergic neuronal cells or substantia nigra neurons results 
in the development of experimental autoimmune nigral damage 
with symptoms resembling human PD (53, 54). PD has been 
associated with the loss of vesicular monoamine transporter-2 
(VMAT2) in dopamine-producing neurons resulting in elevated 
levels of cytoplasmic dopamine, which is highly neurotoxic 
(55, 56). Injection of animals with the VMAT2 antagonist 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) leads 
to necroptosis of dopamine-producing neurons due to the 
accumulation of neurotoxic dopamine in the cytoplasm. The 
necroptotic dopamine-producing neurons subsequently induce 
a chronic T cell-mediated and nigral-specific immune response 
that results in the development of the characteristic PD symptoms 
(51, 57). MPTP-induced PD in mice and marmosets are gener-
ally considered the most accurate animal models of human PD. 
VMAT2-knockout mice display the pathology and symptoms of 
PD, whereas VMAT2-knockdown mice are highly susceptible 
to MPTP-induced PD induction (58). On the contrary, animals 
overexpressing VMAT2 have increased striatal dopamine levels 
and are MPTP-resistant (59). These genetic, pharmacological, and 
immunological studies strongly suggest that VMAT2 expressed at 
high levels in dopamine-producing neurons is a candidate pSAg 
involved in the autoimmune destruction of dopamine-producing 
neurons in PD patients (60).
Attention Deficit Hyperactivity Disorder
Attention-deficit hyperactivity disorder symptoms include dif-
ficulties staying focused and paying attention, impulsivity (diffi-
culty in controlling behavior), and hyperactivity. ADHD patients 
have inflammation markers in the blood (61) and white matter 
loss in the striatal, frontal, and parietal, dopamine-innervated 
brain areas (62–64). Mice with knockout and knockdown 
mutations in the dopamine transporter-1 (DAT1) gene show 
severe behavioral changes, including hyperactivity, memory, 
repetitive behavior, and learning deficits, mimicking human 
6de Haan et al. Autoimmune Aspects of NPDs
Frontiers in Psychiatry | www.frontiersin.org April 2017 | Volume 8 | Article 46
ADHD (65–68). Immunization of mice with DAT1 results in 
the development of characteristic ADHD symptoms (64). In 
addition, ADHD patients have a humoral immune response 
to DAT1 (69). Since DAT1 fulfills the three criteria outlined in 
Section “The Candidate Primary Self-Antigens of NPDs,” it is 
believed that transporter is the pSAgs involved in the autoim-
mune damage of the dopaminergic striatal and cortical neurons 
in ADHD patients. Furthermore, these studies suggest that 
DAT1 is predominantly expressed in post-synaptic neurons in 
the striatum and frontal–parietal brain areas that are innervated 
by dopamine-producing neurons.
The Reward Deficiency Syndrome
Reward deficiency syndrome comprises substance addiction and 
the obsessive–compulsive disorder (OCD). Substance addiction 
resides in the dopaminergic neurons of the nucleus accumbens 
in the striatum and coincides with increased inflammation 
markers in the affected compartment (70, 71). The chronic and 
disabling obsessional thoughts and compulsive rituals of OCD 
patients are associated with hyperactivity of the ventral cognitive 
circuit, involving dopaminergic neurons in the striatum (72, 73). 
OCD coincides with inflammation markers in the blood and the 
striatum (74–77). Drug use leads to elevated levels of dopamine, 
increased dopamine receptor-1 (DAR1), and decreased DAR2 
signaling in the striatum that results in stimulation of the reward 
circuitry (78). In drug addicts, striatal DAR2 levels are reduced 
compared to those in healthy individuals (79). Mutations in 
the gene encoding DAR2 which render the receptor less sensi-
tive to dopamine are associated with addictive behavior (80). 
Downregulation of DAR2 in rats promotes the reward deficits 
resulting in addictive behavior, such as compulsive food-seeking 
(81). DAR2 knockout mice display elevated DA synthesis result-
ing in hyperlocomotion and supersensitivity to drugs, such as 
cocaine (82). DAR2 overexpression in the nucleus accumbens 
of rats attenuates addictive behavior (83). These studies together 
with genetic and pharmacological studies on DAR3 (84–86) 
suggest that a dopamine receptor from the DAR2 family is the 
most likely candidate pSAg of addiction. Pharmacological stud-
ies in mice using dopamine receptor-1 agonists show that these 
drugs induce complex movement sequences such as grooming, 
resembling human OCD (87). Overall, the studies on dopamine 
receptors suggest that they are the candidate pSAgs for the 
reward-associated NPDs, addiction, and OCD.
Group 3: Glutamatergic NPDs
Epilepsy
Epilepsy is a group of diseases characterized by convulsive or 
absence seizures, caused by an improper functioning of gluta-
matergic cortical neuron ion channels. The most common form 
of epilepsy is temporal lobe epilepsy (TLE) in which the seizures 
occur in the hippocampus of patients. Repeated seizures in 
epilepsy patients are associated with immune responses, result-
ing in hippocampal necroptosis and/or cortical damage at the 
site of the seizures (88–90). Treatment with the strong mAChR 
agonist pilocarpine results in N-methyl-D-aspartate (NMDA) 
receptor (NMDAR)-mediated excitotoxicity of hippocampal 
glutamatergic neurons (91). The degeneration of glutamatergic 
neurons coincides with severe epileptic seizures. Pilocarpine-
induced epilepsy in rodents is, therefore, generally considered 
the most accurate animal model of human TLE (92). Patients 
with severe epilepsy symptoms known as Rasmussen encephalitis 
show a humoral immune response to metabotropic Glutamate 
receptor 3 (mGluR3) (93), whereas the affected brain parts are 
also infiltrated by CTLs (94, 95). The CTLs isolated from the 
inflamed brain parts of patients show a limited TCR repertoire, 
suggesting that these CTL’s are clonally derived and recognize a 
single or few self-antigens (19, 96). Agonists of the metabotropic 
group II receptors (mGluR2 and mGluR3) inhibit glutamate 
release in synapses of the glutamatergic hippocampal neurons of 
epilepsy patients and are potent anticonvulsants against motor 
and absence seizures (97), indicating that a shortage of metabo-
tropic group II receptors may cause the generation of seizures in 
epilepsy patients. Immunization of rabbits with mGluR3 induces 
epileptic seizures (98). Immunization of rabbits with mGluR3 (but 
not mGluR1, 2, 5, or 6) results in the development of seizures and 
histopathological changes that mimic Rasmussen’s encephalitis 
(99). These immunological and pharmacological studies indicate 
that mGluR3 is the most likely pSAg involved in the destruction 
of hippocampal and cortical neurons in epilepsy patients.
Schizophrenia
Schizophrenia patients suffer from delusions, hallucinations, a 
distorted awareness, and disorganized thinking during psychotic 
episodes. Schizophrenia is associated with immune responses 
and lymphocyte infiltrations in the hippocampus and a reduced 
hippocampal gray matter size (100–106). It has been suggested 
that reduced striatal glutamate signaling increases the risk of 
sensory overload and of exaggerated responses in the monoamin-
ergic system, consistent with schizophrenia symptoms. NMDAR 
antagonists, such as phencyclidine (PCP), induce schizophrenia 
symptoms, whereas NMDAR agonists are schizophrenia 
medicines. Mice mutants with reduced NMDAR levels develop 
symptoms resembling schizophrenia, which can be overcome by 
treatment with NMDAR agonists (107, 108). This suggests that 
NMDAR is a candidate pSAg involved in the striatal damage of 
schizophrenia patients (109).
Among the acute autoimmune encephalopathies anti-
NMDAR encephalitis is the most prevalent. Patients generally 
show epileptic and/or schizophrenic symptoms indicating that 
hippocampal glutamatergic circuits are affected. It has remained 
unknown whether NMDAR is the pSAg or a secondary self-
antigen of the disease. The encephalitis is treated by removal 
of the coinciding ovary teratoma that presents hippocampal 
pSAgs or by using anti-inflammatory drugs. The few remaining 
therapy-resistant anti-NMDAR encephalitis patients represent 
epilepsy and/or schizophrenia patients depending on the disease 
symptoms shown (110).
Group 4: Histaminergic NPDs
Tic Disease
Patients with a tic disease including the Tourette syndrome show 
spontaneous short muscle contractions resulting in movements 
7de Haan et al. Autoimmune Aspects of NPDs
Frontiers in Psychiatry | www.frontiersin.org April 2017 | Volume 8 | Article 46
(motor tics) or vocals (vocal tics). Markers of inflammation 
are found in the basal ganglia and in the peripheral blood. 
Histaminergic neurons in the basal ganglia are targeted by the 
patient’s immune system (111, 112). Mice with a knockout muta-
tion in the histidine decarboxylase gene that lack the capacity to 
produce histamine show tic-like stereotypes (113). These genetic 
and pharmacological studies suggest that the histamine 3 recep-
tor is the pSAg of TD (114).
Group 5: Serotonergic NPDs
Depression
Depression comprises bipolar or manic depression and unipolar 
or major depression. Patients usually undergo periods of mania 
and/or often severe depression. Depression is associated with 
decreased serotonergic activity in the prefrontal cortex, amyg-
dale and/or hippocampus, inflammation markers in the brain 
and periphery, and a reduced size of the prefrontal cortex (115, 
116). Imaging and post mortem studies in patients with severe 
depression revealed damage of specific parts in the prefrontal 
cortex (117–119) associated with leukocyte infiltrates from 
the periphery (120, 121). Depression is caused by a shortage 
of 5-hydroxytryptamine (5-HT) transporter (5-HTT) activity 
resulting in overstimulation of glutamatergic neurons in the 
prefrontal cortex upon stress (122). Indeed, 5-HTT knockout 
mice and rats show depression-related behavior with impaired 
neural plasticity (123, 124), suggesting that 5-HTT is the pSAg 
of depression. Selective serotonin reuptake inhibitors (SSRIs) are 
widely-prescribed to treat depression (125). The genetic studies 
using 5-HTT knockout animals, therefore, seem to be in conflict 
with the pharmacological studies using SSRIs. A possible expla-
nation for this discrepancy could be that SSRIs serve as 5-HT 
receptor (5-HTR) agonists rather than 5-HTT antagonists (126).
Anxiety
Anxiety includes general anxiety, panic disease, and phobias. 
Anxiety coincides with decreased serotonergic activities in the 
raphe nuclei in the brain stem (127, 128). Studies using mouse 
strains with knockout or conditional knockout mutations in 
genes involved in serotonin or 5-hydroxytryptamine (5-HT) 
metabolism and strains overexpressing these genes, combined 
with pharmacological studies using SSRIs revealed that anxiety 
is caused by a shortage of 5-HT perception, resulting in defective 
glutamate signaling in the prefrontal cortex upon stress. These 
studies suggest that one of the serotonin receptors, probably 
receptor 2C (5-HTR2C) is the pSAg of anxiety (129).
NOvel iMMUNOTHeRAPieS TO TReAT 
NPDs
In our aging population, degenerative diseases associated with 
aberrant immune responses, such as diabetes mellitus, arthritis, 
atherosclerotic cardiovascular disease, chronic obstructive 
pulmonary disease, and NPDs, have become highly prevalent 
(130–132). For only a few degenerative diseases more or less 
effective treatments have become available. To date, psychiatric 
diseases are treated with neurotransmitter antagonists/agonists 
that dampen undesired behaviors. A number of anti-inflammatory 
drugs, such as cyclooxygenase inhibitors, minocycline, omega-3 
fatty acids, and neurosteroids, ameliorate the symptoms of 
psychiatric diseases, confirming the role of the patient’s immune 
system in the pathogenesis (133). For the neurodegenerative 
diseases, anti-inflammatory drugs are not sufficient to ameliorate 
or significantly delay disease progression. Only MS drugs that 
inhibit the migration of lymphocytes from the periphery to the 
CNS decrease the frequency of disease relapses.
Overall, all current treatments, if available, non-specifically 
suppress inflammation and only decrease the frequency of 
relapses and thus alleviate disease symptoms. Long-term use of 
non-specific immuno-suppressing medication coincides with 
often severe adverse side effects and enhances the risk of develop-
ing cancer or autoimmune processes in other tissues. There is, 
therefore, an urgent need for novel treatments of degenerative 
diseases in general and NPDs in particular that specifically inhibit 
tissue damage caused by activated cells of the adaptive immune 
system, leaving the general immune response unaffected. In 
principle, this should be feasible since autoimmune diseases are 
acquired diseases by individuals with fully functional immune 
systems.
Restoration of the immune tolerance to the pSAgs involved 
in the autoimmune tissue destruction, also named reverse vac-
cination, has been a longstanding goal in autoimmunity research. 
This has been attempted by administration of the self-antigens 
or peptide fragments derived thereof to patients (134–137). 
However, naked proteins or peptides are rapidly degraded in 
the body. Linkage of peptides to nanoparticles to improve their 
stability results in a transient effect with a very narrow spectrum 
of activity. The results of such protein/peptide-based tolerization 
approaches pursued so far did not meet the expectations (138).
An efficient way to instruct immune cells for suppressing an 
autoimmune response is to let them produce the self-antigens 
involved in the autoimmune tissue destruction by introducing 
the self-antigen-encoding genes into these cells, in a non-
inflammatory or tolerogenic environment, such as the liver.
For the best-studied autoimmune disease animal models 
(DM1, MS and RA), it has been shown that viral vector-mediated 
expression of the pSAgs of the disease protects the treated animals 
from the autoimmune disease both in prophylactic and thera-
peutic settings (139–142). Viral vector-mediated tolerization, 
e.g., reverse viral vector vaccination, therefore, has an enormous 
potential for effectively treating degenerative diseases, including 
NPDs.
To date, reverse viral vector vaccines have not been tested in 
the clinic. The main reason for this is the immunogenicity or lack 
of in  vivo efficacy of the currently most popular viral vectors, 
adeno-associated viral vectors derived from adeno-associated 
virus (AAV), and lentiviral vectors derived from the human 
immunodeficiency virus type 1 (143, 144). AAV’s immunogenic-
ity in humans, and as a result clinical inefficacy, will remain the 
major challenge for the approval of new AAV-based interven-
tions. Therefore, in order to develop efficient in vivo gene thera-
pies and to efficiently restore immune tolerance in patients with 
a degenerative disease, a new viral gene delivery vector is needed. 
A new vector suitable for use in reverse viral vector vaccinations 
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should combine the in vivo efficacy of AAV vectors in animals 
with being non-immunogenic in humans.
Only for the well-studied autoimmune diseases, the pSAgs 
are known and have been used in preclinical reverse viral vector 
 vaccination studies (139–142). For some NPDs, such as MS, AD, 
ALS, ADHD and epilepsy candidate pSAgs have been identified 
(see The Candidate Primary Self-Antigens of NPDs), but for 
other important NPDs no clear candidate pSAgs involved in 
disease progression have been identified. All patients with an 
autoimmune disease have an adaptive immune response to the 
pSAg of the disease. Immunization of animals with a pSAg of an 
autoimmune disease results in the development of the charac-
teristic disease symptoms (23, 28, 37, 64, 98, 99). Therefore, in 
order to verify whether a candidate self-antigen is the pSAg of the 
disease, immunological studies as described above are needed.
Once the vector immunogenicity and pSAg identification hur-
dles are taken, reverse viral vector vaccination has the potential to 
yield a whole new range of therapeutics and even prophylactics 
addressing today’s major diseases, which will dramatically change 
the medicine landscape.
This is particularly relevant for the highly mortal and severely 
debilitating NPDs. Effective reverse vaccines will halt neurode-
generation in patients with a neurodegenerative disease and will 
stop chronic or flaring inflammation in the CNS of psychiatric 
patients rendering them amenable to existing psychotherapy.
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